Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

Emerging immunotherapy combination strategies in genitourinary malignancies

Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

Emerging targeted therapy combination strategies in genitourinary malignancies

Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer